Latest Biotech News

Guardant Health struck a strategic collaboration with Zephyr AI to combine Guardant’s multimodal molecular datasets from its genomic testing platform with Zephyr’s AI and machine learning...

Hemab Therapeutics closed a $157 million financing to advance a portfolio targeting ‘underserved’ coagulation disorders, including a pivotal program for Glanzmann thrombasthenia and an early...

Ena Respiratory closed an AU$34 million (US$22.4 million) Series B to advance INNA‑051, a nasal spray candidate for symptomatic viral respiratory infections, into Phase II. Investors include the...

Novartis agreed to acquire Avidity Biosciences for roughly $12 billion, taking ownership of three late-stage antibody-oligonucleotide conjugate (AOC) programs targeting neuromuscular diseases. The...

Intellia Therapeutics paused enrollment and dosing in two Phase 3 trials of its in vivo CRISPR candidate after a study volunteer was hospitalized with severe liver toxicity. The company said it is...

GSK struck an exclusive license with Empirico for an inhaled siRNA candidate targeting non‑type 2 inflammatory COPD, paying $85 million upfront and up to hundreds of millions in milestones. The...

Zenas Biopharma reported a midstage (MoonStone) trial result showing a ~95% reduction in new Gd‑enhancing brain lesions at Weeks 8–12 with obexelimab versus placebo in relapsing multiple...

BridgeBio posted an interim Phase 3 readout for BBP‑418 in LGMD2I/R9 that the company described as a potential 'home run,' prompting plans to meet the FDA to discuss an NDA submission. The interim...

Zag Bio launched with an $80 million Series A to develop thymus‑targeted bifunctional antibodies designed to induce regulatory T cells (Tregs) for autoimmune disease. The round included strategic...

Danaher subsidiary Cepheid’s Xpert MTB/XDR assay received World Health Organization prequalification for genotypic detection of resistance to multiple first‑ and second‑line tuberculosis drugs....

Revvity reported that its diagnostics business grew in Q3 driven by newborn screening and immunodiagnostics, with diagnostics revenue rising 3% year over year. Company executives cited new...

The U.S. Pharmacopeia released reference standards and analytical reference materials to help manufacturers ensure purity and detect impurities in GLP‑1 peptide products amid unprecedented demand...

Hemab Therapeutics closed a $157 million financing to advance a portfolio targeting rare bleeding disorders including Glanzmann thrombasthenia and von Willebrand disease. The round was led by...

Novartis agreed to acquire Avidity Biosciences in a roughly $12 billion cash deal that brings three late‑stage antibody‑oligonucleotide conjugate (AOC) programs into its neuroscience portfolio....

Intellia Therapeutics paused enrollment and dosing in two Phase III trials of its in vivo CRISPR candidate (nex‑z) after a study participant was hospitalized with severe liver injury. The company...

BridgeBio reported a positive interim Phase III readout for BBP‑418 in limb‑girdle muscular dystrophy 2I/R9, meeting pre‑specified efficacy thresholds and prompting plans to meet the FDA to...

Zenas Biopharma announced mid‑stage MoonStone data showing its bifunctional monoclonal antibody obexelimab produced a 95% reduction in new gadolinium‑enhancing brain lesions in relapsing multiple...

Hemab Therapeutics closed a $157 million financing to advance a portfolio focused on rare and underserved coagulation disorders, including lead programs moving toward pivotal testing. The funds...

Researchers at the Earlham Institute released MARTi, an open‑source software suite enabling real‑time analysis and visualization of nanopore metagenomic data. MARTi combines a lightweight analysis...

An MIT‑led team unveiled BoltzGen, a supercomputer‑trained AI model that moves beyond high‑accuracy structure prediction to generalizable therapeutic design across modalities — nanobodies,...